How to Sell an ABA Therapy Business in 2026

Applied Behavior Analysis has been one of the most heavily PE-backed corners of pediatric healthcare for the last decade. The Stepping Stones Group, Hopebridge, Autism Learning Partners, Behavioral Innovations, Action Behavior Centers, LEARN Behavioral, Centria Autism, and Invo Healthcare all have active platform strategies. In a typical year there are 40-60 ABA transactions, and while multiples have compressed from the 12-14x EBITDA peak of 2021, well-run mid-market ABA businesses still trade at 7-10x EBITDA.

The caveat: ABA is a services business where the entire asset walks out the door every night. If your BCBAs quit after the deal closes, the buyer has nothing. Every sophisticated ABA buyer underwrites BCBA retention risk first and revenue trends second. The sellers who maximize value understand this and run the process accordingly.

BCBA Retention Is the Whole Ball Game

Board Certified Behavior Analysts are the clinical supervisors who write treatment plans, supervise RBTs, and are named on every insurance authorization. Lose a BCBA, and you lose their caseload — often 8-12 kids each. Buyers know the industry-wide BCBA turnover rate runs 25-35% annually, and they price deals assuming 20-25% of your BCBAs will leave within 12 months of closing regardless of what you tell them.

Your job as a seller is to prove your BCBA retention is better than the industry average. Pull your HR records and document BCBA tenure by individual — buyers want to see a weighted average tenure of 2.5+ years and voluntary turnover under 20%. If you're above that, highlight it relentlessly in the CIM. If you're below, fix it before you go to market.

The single most effective retention lever in ABA is caseload. BCBAs burn out when they're supervising 14+ clients. Sustainable caseloads run 10-12 clients per BCBA, with protected admin time for treatment planning and parent training. Practices that hit those numbers retain clinicians. Practices pushing BCBAs to 16 clients to juice margins look great on a TTM EBITDA printout and then hemorrhage staff six months after closing.

Consider a stay bonus pool. A common structure: the seller carves out 2-4% of transaction proceeds into a bonus pool for BCBAs and regional leadership, payable 12-24 months post-close contingent on continued employment. Buyers love it because it aligns retention. Sellers love it because it's tax-efficient and often a condition of getting a premium multiple.

Insurance Authorizations Don't Transfer Cleanly

Every ABA client has a prior authorization tied to a specific provider tax ID and NPI. When the practice changes hands, those authorizations do not automatically follow. This is one of the most underappreciated transaction risks in ABA, and it's caused real revenue disruption in deals I've worked on.

Before closing, the buyer and seller need a detailed authorization transfer plan. For every major payer — Aetna, BCBS state plans, Cigna, Optum, Magellan, Kaiser, state Medicaid plans, TRICARE — document the current auth count, hours authorized per week, auth expiration dates, and the payer's specific CHOW or provider change process. Some payers require new auths under the buyer's tax ID. Others allow successor-in-interest assignment. A few require the client's parent to sign a new consent form.

Budget for a 5-15% temporary revenue dip in the 60-90 days post-close as auths get re-issued. Sophisticated buyers will build this into their model and won't penalize you for it. Unsophisticated buyers will try to re-trade when billings dip. Protect yourself with clear deal documentation about auth transfer responsibility and a standard working capital true-up rather than a revenue-based purchase price adjustment.

Credentialing, Billing, and Payer Mix

ABA billing is technical. The CPT code set (97151 assessment, 97153 direct therapy, 97155 protocol modification, 97156 parent training, 97158 group) has specific documentation and supervision requirements, and payers audit aggressively. Before going to market, run a billing compliance review — ideally an independent audit by a firm like Milliman, BHI Billing, or Missing Piece — to document that your billing is clean.

Payer mix drives multiples here too. Commercial-heavy practices (70%+ commercial) trade at higher multiples than Medicaid-heavy ones because rates are higher and more stable. Medicaid rates vary wildly by state: Texas pays well, California is decent, Florida and Illinois are challenging. If you operate across multiple states, segment your financials by state so buyers can see which markets drive EBITDA.

Credentialing hygiene matters as much as it does in mental health. Every BCBA and RBT credentialed with every payer, no lapses, CAQH profiles current. Pull a full credentialing report before you engage a banker — if your credentialing company (Medallion, Verifiable, or in-house) can't produce one in 48 hours, that's a problem you need to fix.

What Buyers Pay For in ABA

Here's the short list of what commands premium ABA multiples:

• BCBA tenure over 2.5 years and voluntary turnover under 20%.
• Center-based delivery over pure in-home — better clinical oversight, higher RBT productivity, lower no-show rates.
• RBT utilization over 65% of scheduled billable hours actually billed.
• Diversified payer mix with no single payer over 30% of revenue.
• Clinical outcomes data using standardized assessments (VB-MAPP, ABLLS-R, Vineland).
• Real estate owned or long-term leases with renewal options for center-based locations.
• Middle management layer — clinical directors, regional managers, credentialing staff — that runs without the founder.

Running the Process

For ABA practices with $2M+ in EBITDA, hire a healthcare banker who has closed ABA deals. Provident Healthcare Partners, Edgemont, Cross Keys, Coker Capital, and MHT Partners all have active ABA practices. Get sell-side QofE done before the CIM goes out — ABA EBITDA calculations are messy (productivity adjustments, RBT training time, stock comp, founder add-backs) and buyers will challenge every number.

Expect 8-10 months from banker engagement to close. Deal structures commonly include 70-85% cash at close, 10-20% rollover equity into the platform, and a 1-2 year earnout tied to BCBA retention and EBITDA performance. The rollover equity piece is a double-edged sword — if the platform exits well in 3-5 years, your rollover can be worth more than your original sale. If it doesn't, it's worth zero. Size your rollover based on your conviction in the buyer's platform, not on their fee pitch.

What to Fix Before You Go to Market

Right-size BCBA caseloads. If your BCBAs are supervising 14+ clients to juice near-term margin, rebalance to 10-12 per BCBA 6-12 months before going to market. Retention will improve, turnover data will look better, and buyers will price the trend not the snapshot.

Clean up your EHR data. CentralReach, Rethink, Catalyst, and Therapy Brands are the dominant ABA practice management platforms. Whichever you use, make sure you can export clinician-level productivity, client auths, session notes, and billing data in structured form. If the report doesn't exist, build it — diligence moves fast and buyers lose patience with sellers who can't produce basic operational reports.

Document your outcomes. Even a simple VB-MAPP pre/post dashboard showing measurable skill acquisition for your clients is a differentiator. Buyers are increasingly asked by their LPs and by MA plans to demonstrate clinical outcomes, and they pay for sellers who already do it.

Convert RBTs to W-2 where you haven't already. The Department of Labor's independent contractor rule and state-level classifications (especially California AB5) make 1099 RBT arrangements increasingly hard to defend. Convert before diligence finds it.

Secure your real estate. Center-based ABA businesses live and die on lease terms. A 7-10 year lease with renewal options is a real asset. Leases with under 3 years remaining are a liability that will compress your multiple.

The Bottom Line

ABA multiples have normalized from the 2021 peak, but the best operators still trade at 8-10x EBITDA because there's a long line of PE-backed platforms hunting for quality add-ons. What separates a premium exit from an average one in ABA is BCBA retention, clinical compliance, and clean authorization data. Spend 12 months locking those down, then run a competitive process — and expect the buyer to do their diligence right.